Parminder studied medicine at The University of Birmingham (2001-2006). She began training in nephrology in Oxford in 2010.
Parminder has taken time “out-of-programme for research” from her nephrology training and joined the Renal Studies Group at CTSU in 2013 as a Clinical Research Fellow. She works on the UK Heart and Renal Protection (HARP)-III trial, which is testing new treatments in patients with chronic kidney disease and has also worked on the 3C trial.
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.
Gross O. et al, (2017), Nephrol Dial Transplant, 32, 916 - 924
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: UK Heart and Renal Protection (UK HARP)-III. Rationale, trial design and baseline data.
Haynes R. and Judge P., Nephrology, Dialysis and Transplantation